The US prescribing information for Ozempic does not mention alcohol anywhere, and its drug interactions section covers only insulin secretagogues and other oral drugs. There is no labelled alcohol interaction and no instruction to avoid drinking, because no interaction study was submitted either way.
What has been studied is the opposite question. In a 2025 randomised trial of 48 adults with alcohol use disorder, nine weeks of semaglutide at 0.25 mg to 1.0 mg weekly reduced the amount consumed in a laboratory drinking task and cut weekly craving (PMID 39937469). Here is what each trial found, where the nulls are, and which labelled risks genuinely intersect with drinking.
- Neither the Ozempic nor the Wegovy labelling mentions alcohol at all.
- Three labelled risks overlap with drinking: hypoglycaemia when combined with insulin or a sulfonylurea, acute pancreatitis, and kidney injury from volume depletion.
- A 48-participant semaglutide trial met its primary endpoint on laboratory alcohol intake; an oral semaglutide trial and a 127-patient exenatide trial both missed theirs.
- A 40,703-adult cohort study found hazard ratios of 0.35 to 0.78 for alcohol-related hospitalisation after starting semaglutide or tirzepatide.
- No GLP-1 drug is approved for alcohol use disorder anywhere, and the randomised evidence is two phase 2 trials of eight and nine weeks.
What the label says, and what it leaves out
The Ozempic prescribing information does not mention alcohol once. Its drug interactions section has exactly two subsections: concomitant use with an insulin secretagogue or insulin, and the effect on other oral drugs. The Wegovy labelling is the same on this point.
That silence is not an endorsement. It means no interaction study was run and no warning was warranted on the evidence submitted. Three labelled risks do intersect with drinking, and they are worth naming precisely:
- Hypoglycaemia with insulin or a sulfonylurea. Semaglutide alone works in a glucose-dependent way, which is why hypoglycaemia is uncommon on its own. The label's warning applies to combination with insulin or an insulin secretagogue. Alcohol independently impairs the liver's ability to release glucose, so that is the combination where the two meet.
- Acute pancreatitis. A labelled warning for the class, with instructions to discontinue if pancreatitis is suspected. Heavy alcohol use is itself among the leading causes of acute pancreatitis, so the two risks sit on the same organ.
- Acute kidney injury from volume depletion. The label ties this to adverse reactions that cause fluid loss, which is to say vomiting and diarrhoea. Alcohol adds to fluid loss rather than offsetting it.
None of that is an instruction. It is the set of mechanisms a prescriber would be weighing, and the question of whether to drink at all on these drugs is one to put to them.
The randomised trials run in the opposite direction
The interesting evidence on GLP-1 drugs and alcohol is not about safety. It is about whether these drugs reduce drinking, and three randomised controlled trials have now tested it directly.
| Trial | Drug and dose | Participants | Duration | Primary outcome |
|---|---|---|---|---|
| Hendershot 2025 (PMID 39937469) | Semaglutide 0.25 mg, then 0.5 mg, then 1.0 mg weekly | 48 non-treatment-seeking adults with alcohol use disorder | 9 weeks | Met: less alcohol consumed in a laboratory self-administration task |
| Schacht 2026 (PMID 42522065) | Oral semaglutide 3 mg daily, then 7 mg daily | 50 treatment-seeking adults with moderate to severe alcohol use disorder | 8 weeks | Not met: no significant reduction in cue-elicited craving |
| Klausen 2022 (PMID 36066977) | Exenatide 2 mg weekly plus cognitive behavioural therapy | 127 treatment-seeking adults with alcohol use disorder | 26 weeks | Not met: no significant reduction in heavy drinking days |
In Hendershot's trial, the laboratory measure showed medium to large effects on grams of alcohol consumed (beta -0.48, 95% CI -0.85 to -0.11) and on peak breath alcohol concentration (beta -0.46, 95% CI -0.87 to -0.06). Semaglutide did not change drinks per calendar day or the number of drinking days, but it did reduce drinks per drinking day and weekly alcohol craving. The doses tested, 0.25 mg to 1.0 mg weekly, sit inside the Ozempic range rather than at the 2.4 mg weight-management dose.
Schacht's oral semaglutide trial missed its primary endpoint but hit several preregistered secondary ones: fewer heavy drinking days, fewer drinks per drinking day, lower naturalistic craving, fewer alcohol-related consequences, and significantly more participants dropping at least one World Health Organization risk drinking level. Cannabis use days fell as well.
Klausen's exenatide trial is the most instructive null. It missed on heavy drinking days across the whole sample, but imaging showed attenuated alcohol cue reactivity in the ventral striatum and septal area, both central to reward processing, along with lower dopamine transporter availability. In an exploratory subgroup with a BMI above 30, exenatide did significantly reduce heavy drinking days and total alcohol intake.
The cohort signal is larger and messier
A 2026 target trial emulation using electronic health records from a collective of US health systems identified 40,703 adults with alcohol use disorder plus either type 2 diabetes or obesity, and compared those starting semaglutide or tirzepatide with matched comparators across four parallel analyses (PMID 42481079).
Starting a newer GLP-1 drug was associated with a lower one-year hazard of alcohol-related emergency visits or hospitalisation in every one: hazard ratio 0.74 against sulfonylureas and 0.78 against other diabetes medicines, 0.68 against other anti-obesity medicines, and 0.37 and 0.35 against medications for alcohol use disorder in the diabetes and obesity cohorts.
Those are observational comparisons, with all the confounding by indication that implies, and a non-alcohol-related hospitalisation outcome was included as a negative control. The direction is consistent with the trials even if the magnitude is not directly comparable.
What this does not mean
None of the above makes a GLP-1 drug a treatment for drinking. The randomised evidence consists of two phase 2 trials with 48 and 50 participants over eight and nine weeks, one of which missed its primary endpoint, plus a 127-patient exenatide trial that also missed its primary endpoint. No GLP-1 receptor agonist is approved for alcohol use disorder in any jurisdiction, and the authors of the positive trial describe continued development as warranted rather than established.
The mechanism being proposed, an effect on reward signalling rather than on appetite alone, is also a live hypothesis rather than a settled one. What the appetite side of the mechanism actually measures is covered in how semaglutide works.
The practical overlap nobody has studied
Three ordinary interactions sit outside the labelled risks and outside the trials.
Gastrointestinal symptoms are the most common adverse reactions on these drugs, with nausea reported in 35% of adults on semaglutide 2.4 mg against 13% on placebo, and alcohol irritates the same system. We go through the frequency and duration of each symptom in semaglutide side effects.
Alcohol is also dense in calories that the drug's appetite effect does nothing about, since the measured mechanism works on food intake. And a number of people on these drugs report a spontaneous drop in how much they want to drink, which is consistent with the craving findings above but is not something any trial measured as a reason to change anything.
What none of that adds up to is a rule. It adds up to a conversation with the prescriber, who knows what else is on the prescription.
The weight side of the same question
See what the published trial percentages work out to from your own starting weight.
If you came here from the weight side of the question, the GLP-1 weight loss calculator puts the published trial percentages against a starting weight, which is the context most of these numbers are missing.
FAQ
Can you drink alcohol on Ozempic?
The Ozempic prescribing information does not mention alcohol, and its drug interactions section covers only insulin secretagogues and other oral drugs, so there is no labelled interaction. That reflects the absence of an interaction study rather than a finding of safety, and the decision belongs with the prescriber, particularly for anyone also taking insulin or a sulfonylurea.
Does semaglutide reduce how much you want to drink?
In a randomised trial of 48 adults with alcohol use disorder, nine weeks of semaglutide reduced the amount consumed in a laboratory drinking task, drinks per drinking day and weekly craving, though not the number of drinking days. A separate oral semaglutide trial in 50 adults missed its craving endpoint but reduced heavy drinking days and alcohol-related consequences.
Is semaglutide approved to treat alcohol use disorder?
No. No GLP-1 receptor agonist is approved for alcohol use disorder in any jurisdiction. The randomised evidence consists of two phase 2 trials with 48 and 50 participants over nine and eight weeks, plus a 127-patient exenatide trial that missed its primary endpoint.
What are the real risks of drinking on a GLP-1?
The labelled risks that intersect with alcohol are hypoglycaemia when the drug is combined with insulin or a sulfonylurea, acute pancreatitis, which heavy drinking independently causes, and acute kidney injury from volume depletion when vomiting or diarrhoea are already present. Alcohol also irritates the same gastrointestinal system that produces the most common adverse reactions.
Why do some people say they drink less without trying?
That report is consistent with the craving findings in the randomised trials and with imaging in the exenatide trial, which showed attenuated alcohol cue reactivity in the ventral striatum and septal area. It is a hypothesis about reward signalling rather than an established mechanism.
Does alcohol stop a GLP-1 from working?
No trial has tested that. The measured mechanism of these drugs is a reduction in food intake, which alcohol calories are not subject to, so the straightforward point is that drinks add energy the appetite effect does not reach.
Sources
- Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(4):395-405. PMID: 39937469
- Schacht JP, Sakai JT, Raymond K, Shelton R. Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial. Am J Psychiatry. 2026;183(9):636-645. PMID: 42522065
- Klausen MK, Jensen ME, Moller M, et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022;7(19):e159863. PMID: 36066977
- Rodriguez PJ, Lusk JB, Mehta HB, et al. Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study. BMJ Open. 2026;16(7):e109259. PMID: 42481079
- Ozempic (semaglutide) injection, US prescribing information, Novo Nordisk. Section 7 Drug Interactions; no alcohol interaction is listed.
- Wegovy (semaglutide) injection, US prescribing information, Novo Nordisk, revised June 2026. Warnings and precautions 5.2, 5.4 and 5.5; section 6.1 adverse reaction rates.
This article is for information only and is not medical advice. Dosing, suitability and any change to treatment are decisions for your prescriber.